Another NASH Failure: Gilead’s Hits Keep Coming
Executive SummaryThe failure of the STELLAR-3 trial of selonsertib had been widely anticipated following the failure in a sicker population in STELLAR-4.
You may also be interested in...
HIV remains the main growth franchise for Gilead, despite an anticipated first quarter revenue downturn due to inventory and payer mix. Biktarvy’s launch and growth in PrEP business provide multiple drivers for the franchise.
At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.